Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 15/20 | 0.61 |
| ▸ | PROKR1 | Q8TCW9 | 15/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15548422 | 0.79 | ALDH1A1 (0.57) | FPR2PROKR1ALDH1A1NPSR1 | |
| SCHEMBL15548928 | 0.77 | FPR2 (0.79) | FPR2PROKR1LMNAALDH1A1 | |
| SCHEMBL15549092 | 0.76 | FPR2 (1.00) | FPR2PROKR1 | |
| SCHEMBL15550341 | 0.76 | FPR2 (1.00) | FPR2PROKR1 | |
| SCHEMBL15549032 | 0.76 | FPR2 (1.00) | FPR2PROKR1 | |
| SCHEMBL15549371 | 0.76 | FPR2 (1.00) | FPR2PROKR1LMNA | |
| SCHEMBL15549733 | 0.75 | FPR2 (1.00) | FPR2PROKR1 | |
| SCHEMBL15550145 | 0.75 | FPR2 (0.66) | FPR2PROKR1LMNA | |
| SCHEMBL15548339 | 0.75 | FPR2 (1.00) | FPR2PROKR1 | |
| SCHEMBL15549438 | 0.75 | FPR2 (1.00) | FPR2PROKR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | ASTEX THERAPEUTICS LIMITED (UK) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306069-A1 | Pyrazole Derivatives for the Inhibition of CDK'S and GSK'S | GSK3A, CDK11A, CDK1 | FPR2 4574/4885PROKR1 1805/4885TP53 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.